Rise of Local Pharma Industry in Pakistan

The Exit of Multinational Pharmaceutical Companies from Pakistan – Part 3 – Asrar Qureshi’s Blog Post #1293

Asrar Qureshi’s blog discusses the exit of multinational pharmaceutical companies from Pakistan and the country’s potential to attract them back. Highlighting necessary reforms in pricing, regulation, and clinical research, it stresses a long-term vision for the pharmaceutical sector as vital for economic growth and public health security. Collaboration between domestic and multinational firms is essential for success.

View Post

6 min

The Exit of Multinational Pharmaceutical Companies from Pakistan – Part 2 – Asrar Qureshi’s Blog Post #1292

This blog post by Asrar Qureshi examines the exit of multinational pharmaceutical companies from Pakistan, analyzing its historical context and impacts on the healthcare system. While local firms maintain medicine availability, concerns arise regarding innovation and clinical research. The challenge remains to balance local manufacturing capabilities with the need for multinational investment and research.

Scientist pipetting liquid into a tray in a laboratory setting with lab equipment and computer displaying graphs

View Post

6 min

Why Multinational Pharmaceutical Companies Are Leaving Pakistan – Asrar Qureshi’s Blog Post #1291

Asrar Qureshi’s blog post discusses the exit of multinational pharmaceutical companies from the Pakistani market, highlighting historical contributions, major exits, and the challenges faced by these firms, such as drug price controls and currency depreciation. Despite local companies acquiring many brands, concerns about access to innovative therapies and a decline in research presence persist.

View Post

6 min

Strategy Meetings in Pharma Industry – Asrar Qureshi’s Blog Post #1126

Asrar Qureshi’s blog post critiques the repetitive nature of annual strategy retreats in the pharma industry, highlighting their ineffectiveness. He proposes transformative approaches, such as framing retreats around key questions, inviting diverse voices, and fostering cross-functional collaboration. The goal is to inspire genuine innovation and actionable strategies for future success.

View Post

5 min

Why Pakistan’s Pharmaceutical Exports Lag Behind and How to Fix It– Asrar Qureshi’s Blog Post #1124

Pakistan’s pharmaceutical exports are notably low despite having a robust industry, with challenges including inadequate investment in facilities, lack of international certifications, inconsistent compliance with quality standards, and insufficient market intelligence. Strategic reforms, including regulatory improvements and investment in workforce development, are essential for enhancing exports and achieving global competitiveness.

View Post

6 min

Formation of PharmEx Pakistan – Too Late, Too Little? – Asrar Qureshi’s Blog Post #1123

The Ministry of Commerce in Pakistan is launching PharmEx Pakistan to boost pharmaceutical exports, aiming to increase annual exports from $700 million to $3 billion. This public-private initiative, modeled after India’s Pharmexcil, seeks to enhance regulatory compliance and global visibility for Pakistani pharmaceuticals, while facing challenges in international competitiveness.

View Post

4 min

Pharmaceutical Marketing – Stuck in the Past – Asrar Qureshi’s Blog Post #1103

The blog post discusses the stagnation of pharmaceutical marketing due to reliance on outdated strategies, regulatory constraints, and risk aversion. It emphasizes the need for innovation through data-driven personalization, omnichannel engagement, and agile methodologies. A cultural shift toward collaboration and customer-centric approaches is essential for modernization and relevance in a changing landscape.

View Post

5 min

AI and Machine Learning in Pharmaceutical Drug Development – Asrar Qureshi’s Blog Post #1102

The blog post by Asrar Qureshi discusses the transformative impact of Artificial Intelligence (AI) and Machine Learning (ML) on the pharmaceutical industry. It highlights innovations in drug discovery, preclinical development, clinical trials, and manufacturing, emphasizing efficiency and personalized medicine. However, challenges like data privacy and regulatory uncertainty must be addressed.

View Post

5 min

Stressed to Death: When Work Becomes a Silent Killer – Asrar Qureshi’s Blog Post #1096

Asrar Qureshi’s blog post addresses the escalating crisis of workplace stress, particularly within the pharmaceutical industry, linking it to tragic outcomes like premature deaths. It advocates for personal, organizational, and policy-level solutions to combat the stress epidemic, emphasizing the need for a culture that prioritizes employee well-being over relentless productivity.

View Post

5 min

Influence of Gen AI on Pharmaceutical Marketing – Now and in Five Years – Asrar Qureshi’s Blog Post #1088

Asrar Qureshi’s blog discusses the transformative impact of Artificial Intelligence (AI) on pharmaceutical marketing, emphasizing its evolution towards more data-driven, personalized strategies. It highlights current capabilities, like AI in predictive analytics and content creation, while forecasting increased AI integration over the next five years, offering significant advantages to adaptable companies.